Deal Size Increased to 25M Shares, Priced at High End of $16.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 hours ago
0mins
The deal size was increased to 25.0M from 23.3M shares and priced at high end of $14.00-$16.00 range. JPMorgan, Jefferies, Leerink and TD Cowen are acting as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KARD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KARD
Wall Street analysts forecast KARD stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 16.000
Low
Averages
High
Current: 16.000
Low
Averages
High
No data
About KARD
Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kardigan's IPO Soars 37.5% on First Day, Highlighting Biotech Strength
- Kardigan IPO Performance: Biotech firm Kardigan raised $400 million at the high end of its range, achieving a market cap of $1.7 billion, with a first-day stock surge of 37.5%, reflecting strong market confidence in the biotech sector, particularly in cardiovascular disease treatments.
- SpaceX Trading Dynamics: SpaceX's IPO saw a 19% first-day increase, reaching $201.80 by Tuesday's close, a 49% rise from its offering price, although it later fell to $185.00, indicating high market interest and expected volatility in its future performance.
- First Carolina Financial Performance: North Carolina-based First Carolina Financial Services raised $69 million below expectations, with a modest 1% gain on debut; however, its $3.5 billion in assets and commitment to technology investments highlight its significance in the regional economy.
- Deep Fission Financing Situation: Nuclear reactor developer Deep Fission initially aimed to raise $150 million but ultimately secured only $40 million, with a market cap of about $1 billion, reflecting weakened demand for small modular reactors and resulting in a 9% drop in its first-day trading.
See More
Kardigan Shares Surge 15% on First Trading Day After $400M IPO
- First Trading Day Performance: Kardigan (KARD) saw its stock price rise approximately 15% on its first trading day, opening at $16.25, which is about a 2% increase from the IPO price, indicating strong market enthusiasm for its biotech prospects.
- IPO Pricing and Fundraising: The company priced its upsized IPO of 25 million shares at $16 per share on Wednesday, successfully raising $400 million in gross proceeds, exceeding the initial plan of $320.1 million, showcasing investor confidence in its heart disease drug pipeline.
- Market Capitalization: The stock quickly surged to $20.00 shortly after trading began, achieving a market capitalization of approximately $1.8 billion, reflecting strong market recognition of its growth potential, particularly in the cardiovascular treatment sector.
- Future Catalysts: Kardigan is awaiting a topline readout from its Phase 2b/3 trial for its most advanced candidate, danicamtiv, targeting genetic dilated cardiomyopathy, with results expected in H1 2027, marking a critical moment for the company's future development.
See More
Kardigan Shares Rise 1.6% in Nasdaq Debut After $400 Million IPO
- IPO Performance: Kardigan raised $400 million in its Nasdaq debut, with shares rising 1.6%, indicating strong market confidence in its heart drug development.
- Increased Financing: The upsized IPO provides Kardigan with additional funding to accelerate the development of heart drugs, thereby strengthening its position in the competitive pharmaceutical market.
- Positive Market Reaction: The initial positive response from investors, reflected in the stock price increase, suggests recognition of Kardigan's future growth potential, which may attract further investor interest.
- Strategic Implications: The successful IPO not only provides Kardigan with essential funding but also lays the groundwork for future product development and market expansion, enhancing its competitiveness in the heart disease treatment sector.
See More
Kardigan Raises $400 Million in IPO for Cardiovascular Therapies
- Funding Achievement: Kardigan successfully raised $400 million by offering 25 million shares at $16 each, exceeding the anticipated 1.7 million shares, indicating strong market demand for its cardiovascular therapies.
- Clinical Advancements: The company is advancing three late-stage product candidates, including danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension, showcasing its R&D potential in the cardiovascular space.
- Data Platform: Kardigan operates the Prolaio platform, which integrates FDA-cleared algorithms and wearable sensors to collect continuous real-world physiologic data from patients during clinical trials, enhancing the efficiency and accuracy of clinical research.
- Market Positioning: As an emerging biotech firm, Kardigan will trade on Nasdaq under the symbol KARD, expected to attract investor interest due to its innovative treatment solutions and market prospects.
See More
Kardigan Sets IPO Price at $16, Aiming for $400M
- IPO Pricing Announcement: Kardigan has priced its initial public offering at $16 per share for 25 million shares, projecting total gross proceeds of $400 million, indicating strong market demand for its cardiovascular therapies.
- Increased Financing Target: Originally planning to sell 23.3 million shares to raise approximately $350 million, the expansion of the offering reflects investor confidence and the potential of Kardigan's market, raising the target to $400 million.
- Trading Schedule: The company's stock is set to begin trading on June 18, 2026, on the Nasdaq Global Market, with the offering expected to close on June 22, 2026, subject to customary regulatory conditions.
- Underwriting Syndicate: J.P. Morgan, Jefferies, Leerink Partners, and TD Securities are serving as joint book-running managers for the offering, enhancing market trust and support for Kardigan's IPO.
See More
Kardigan's IPO Soars 37.5% on First Day, Highlighting Biotech Strength
- Kardigan IPO Performance: Biotech firm Kardigan raised $400 million at the high end of its range, achieving a market cap of $1.7 billion, with a first-day stock surge of 37.5%, reflecting strong market confidence in the biotech sector, particularly in cardiovascular disease treatments.
- SpaceX Trading Dynamics: SpaceX's IPO saw a 19% first-day increase, reaching $201.80 by Tuesday's close, a 49% rise from its offering price, although it later fell to $185.00, indicating high market interest and expected volatility in its future performance.
- First Carolina Financial Performance: North Carolina-based First Carolina Financial Services raised $69 million below expectations, with a modest 1% gain on debut; however, its $3.5 billion in assets and commitment to technology investments highlight its significance in the regional economy.
- Deep Fission Financing Situation: Nuclear reactor developer Deep Fission initially aimed to raise $150 million but ultimately secured only $40 million, with a market cap of about $1 billion, reflecting weakened demand for small modular reactors and resulting in a 9% drop in its first-day trading.
See More
Kardigan Shares Surge 15% on First Trading Day After $400M IPO
- First Trading Day Performance: Kardigan (KARD) saw its stock price rise approximately 15% on its first trading day, opening at $16.25, which is about a 2% increase from the IPO price, indicating strong market enthusiasm for its biotech prospects.
- IPO Pricing and Fundraising: The company priced its upsized IPO of 25 million shares at $16 per share on Wednesday, successfully raising $400 million in gross proceeds, exceeding the initial plan of $320.1 million, showcasing investor confidence in its heart disease drug pipeline.
- Market Capitalization: The stock quickly surged to $20.00 shortly after trading began, achieving a market capitalization of approximately $1.8 billion, reflecting strong market recognition of its growth potential, particularly in the cardiovascular treatment sector.
- Future Catalysts: Kardigan is awaiting a topline readout from its Phase 2b/3 trial for its most advanced candidate, danicamtiv, targeting genetic dilated cardiomyopathy, with results expected in H1 2027, marking a critical moment for the company's future development.
See More
Kardigan Shares Rise 1.6% in Nasdaq Debut After $400 Million IPO
- IPO Performance: Kardigan raised $400 million in its Nasdaq debut, with shares rising 1.6%, indicating strong market confidence in its heart drug development.
- Increased Financing: The upsized IPO provides Kardigan with additional funding to accelerate the development of heart drugs, thereby strengthening its position in the competitive pharmaceutical market.
- Positive Market Reaction: The initial positive response from investors, reflected in the stock price increase, suggests recognition of Kardigan's future growth potential, which may attract further investor interest.
- Strategic Implications: The successful IPO not only provides Kardigan with essential funding but also lays the groundwork for future product development and market expansion, enhancing its competitiveness in the heart disease treatment sector.
See More
Kardigan Raises $400 Million in IPO for Cardiovascular Therapies
- Funding Achievement: Kardigan successfully raised $400 million by offering 25 million shares at $16 each, exceeding the anticipated 1.7 million shares, indicating strong market demand for its cardiovascular therapies.
- Clinical Advancements: The company is advancing three late-stage product candidates, including danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension, showcasing its R&D potential in the cardiovascular space.
- Data Platform: Kardigan operates the Prolaio platform, which integrates FDA-cleared algorithms and wearable sensors to collect continuous real-world physiologic data from patients during clinical trials, enhancing the efficiency and accuracy of clinical research.
- Market Positioning: As an emerging biotech firm, Kardigan will trade on Nasdaq under the symbol KARD, expected to attract investor interest due to its innovative treatment solutions and market prospects.
See More
Kardigan Sets IPO Price at $16, Aiming for $400M
- IPO Pricing Announcement: Kardigan has priced its initial public offering at $16 per share for 25 million shares, projecting total gross proceeds of $400 million, indicating strong market demand for its cardiovascular therapies.
- Increased Financing Target: Originally planning to sell 23.3 million shares to raise approximately $350 million, the expansion of the offering reflects investor confidence and the potential of Kardigan's market, raising the target to $400 million.
- Trading Schedule: The company's stock is set to begin trading on June 18, 2026, on the Nasdaq Global Market, with the offering expected to close on June 22, 2026, subject to customary regulatory conditions.
- Underwriting Syndicate: J.P. Morgan, Jefferies, Leerink Partners, and TD Securities are serving as joint book-running managers for the offering, enhancing market trust and support for Kardigan's IPO.
See More
